Diabetic Peripheral Neuropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Diabetic Peripheral Neuropathy Pipeline Drugs Market Overview

Diabetic neuropathy is nerve damage caused by diabetes. The type of neuropathy occurring in the arms, hands, legs, and feet is known as diabetic peripheral neuropathy. Symptoms include numbness or tingling in the feet pain or discomfort in the feet or legs-including prickly, sharp pain or burning feet, muscle weakness and loss of muscle tone in the feet and lower legs, loss of balance, dry feet, and cracked skin. The predisposing factors include diabetes, smoking, and kidney diseases. Treatment includes antidepressants, anti-seizure, and opioid analgesics.

The Diabetic Peripheral Neuropathy pipeline drugs market research report provide comprehensive information on the therapeutics under development for Diabetic Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Peripheral Neuropathy and features dormant and discontinued projects.

Key Targets in the Diabetic Peripheral Neuropathy Pipeline Drugs Market

The key targets in the Diabetic Peripheral Neuropathy pipeline drugs market are Transient Receptor Potential Cation Channel Subfamily V Member 1, Aldose Reductase, Heat Shock Protein 90, Muscarinic Acetylcholine Receptor M1, Prostaglandin G/H Synthase 1, Prostaglandin G/H Synthase 2, Bifunctional Epoxide Hydrolase 2, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Free Radical, and others.

Diabetic Peripheral Neuropathy Pipeline drugs Market Analysis by Targets

Diabetic Peripheral Neuropathy Pipeline Products Analysis Market by Targets

For more target insights, download a free report sample

Key Mechanisms of Action in the Diabetic Peripheral Neuropathy Pipeline Products Market

The key mechanisms of action in the Diabetic Peripheral Neuropathy pipeline products market are Aldose Reductase Inhibitor, Heat Shock Protein 90 Inhibitor, Muscarinic Acetylcholine Receptor M1 Antagonist, Prostaglandin G/H Synthase 1 Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, Transient Receptor Potential Cation Channel Subfamily V Member 1 Activator, Bifunctional Epoxide Hydrolase 2 Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Free Radical Scavenger, and others.

Diabetic Peripheral Neuropathy Pipeline Products Market Analysis by Mechanism of Actions

Diabetic Peripheral Neuropathy Pipeline Products Market Analysis by Mechanism of Actions

For more mechanism of actions insights, download a free report sample

Key Routes of Administration in the Diabetic Peripheral Neuropathy Pipeline Drugs Market

The key routes of administration in the Diabetic Peripheral Neuropathy pipeline drugs market are oral, topical, intramuscular, intravenous drip, subcutaneous, sublingual, and transdermal.

Diabetic Peripheral Neuropathy Pipeline Drugs Market Analysis by Routes of Administration

Diabetic Peripheral Neuropathy Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the Diabetic Peripheral Neuropathy Pipeline Products Market

The key molecule types in the Diabetic Peripheral Neuropathy pipeline products market are small molecule, cell therapy, gene therapy, and recombinant protein.

Diabetic Peripheral Neuropathy Pipeline Products Market Analysis by Molecule Type

Diabetic Peripheral Neuropathy Pipeline Products Market Analysis by Molecule Type

For more molecule type insights, download a free report sample

Major Companies in the Diabetic Peripheral Neuropathy Pipeline Products Market

Some of the major companies in the Diabetic Peripheral Neuropathy pipeline products market are Praetego Inc, Medifron DBT Co Ltd, Reata Pharmaceuticals Inc, Winsantor Inc, Achelios Therapeutics Inc, Annji Pharmaceutical Co Ltd, Applied Therapeutics Inc, Celularity Inc, CSPC Pharmaceutical Group Ltd, and Exodos Life Sciences Limited Partnership.

Diabetic Peripheral Neuropathy Pipeline Products Market Analysis by Companies

Diabetic Peripheral Neuropathy Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

Market Report Overview

Key targets Transient Receptor Potential Cation Channel Subfamily V Member 1, Aldose Reductase, Heat Shock Protein 90, Muscarinic Acetylcholine Receptor M1, Prostaglandin G/H Synthase 1, Prostaglandin G/H Synthase 2, Bifunctional Epoxide Hydrolase 2, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Free Radical, and Others
Key mechanism of action Aldose Reductase Inhibitor, Heat Shock Protein 90 Inhibitor, Muscarinic Acetylcholine Receptor M1 Antagonist, Prostaglandin G/H Synthase 1 Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, Transient Receptor Potential Cation Channel Subfamily V Member 1 Activator, Bifunctional Epoxide Hydrolase 2 Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Free Radical Scavenger, and others
Key routes of administration Oral, Topical, Intramuscular, Intravenous Drip, Subcutaneous, Sublingual, and Transdermal
Key molecule type Small Molecule, Cell Therapy, Gene Therapy, and Recombinant Protein
Major companies Praetego Inc, Medifron DBT Co Ltd, Reata Pharmaceuticals Inc, Winsantor Inc, Achelios Therapeutics Inc, Annji Pharmaceutical Co Ltd, Applied Therapeutics Inc, Celularity Inc, CSPC Pharmaceutical Group Ltd, and Exodos Life Sciences Limited Partnership

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Peripheral Neuropathy (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Peripheral Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Peripheral Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Peripheral Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Diabetic Peripheral Neuropathy (Metabolic Disorders)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Peripheral Neuropathy (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Achelios Therapeutics Inc
Annji Pharmaceutical Co Ltd
Applied Therapeutics Inc
Celularity Inc
CSPC Pharmaceutical Group Ltd
Exodos Life Sciences Limited Partnership
G&P Bioscience Co Ltd
GNT Pharma Co Ltd
Grunenthal GmbH
Immune Pharmaceuticals Inc
Ion Channel Pharmacology LLC
Jiangsu Aosaikang Pharmaceutical Co Ltd
Korea United Pharm Inc
Medifron DBT Co Ltd
Mitsubishi Tanabe Pharma Corp
Palisade Bio, Inc
Praetego Inc
Pure Green Pharmaceuticals Inc
Reata Pharmaceuticals Inc
Shandong Huizhi Pharmaceutical Technology Co Ltd
Sonnet BioTherapeutics Holdings Inc
Sphaera Pharma Pte Ltd
Winsantor Inc
Zhejiang Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Diabetic Peripheral Neuropathy – Overview

Diabetic Peripheral Neuropathy – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Diabetic Peripheral Neuropathy – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Diabetic Peripheral Neuropathy – Companies Involved in Therapeutics Development

Achelios Therapeutics Inc

Annji Pharmaceutical Co Ltd

Applied Therapeutics Inc

Celularity Inc

CSPC Pharmaceutical Group Ltd

Exodos Life Sciences Limited Partnership

G&P Bioscience Co Ltd

GNT Pharma Co Ltd

Grunenthal GmbH

Immune Pharmaceuticals Inc

Ion Channel Pharmacology LLC

Jiangsu Aosaikang Pharmaceutical Co Ltd

Korea United Pharm Inc

Medifron DBT Co Ltd

Mitsubishi Tanabe Pharma Corp

Palisade Bio, Inc

Praetego Inc

Pure Green Pharmaceuticals Inc

Reata Pharmaceuticals Inc

Shandong Huizhi Pharmaceutical Technology Co Ltd

Sonnet BioTherapeutics Holdings Inc

Sphaera Pharma Pte Ltd

Winsantor Inc

Zhejiang Pharmaceutical Co Ltd

Diabetic Peripheral Neuropathy – Drug Profiles

(amitriptyline + ketamine hydrochloride) – Drug Profile

Product Description

Mechanism Of Action

History of Events

(diclofenac sodium + triclocarban) – Drug Profile

Product Description

Mechanism Of Action

History of Events

AAD-2004 – Drug Profile

Product Description

Mechanism Of Action

History of Events

AJ-302 – Drug Profile

Product Description

Mechanism Of Action

AT-001 – Drug Profile

Product Description

Mechanism Of Action

History of Events

dextrose lipoic acid tromethamine – Drug Profile

Product Description

Mechanism Of Action

elismetrep – Drug Profile

Product Description

Mechanism Of Action

History of Events

GB-102 – Drug Profile

Product Description

Mechanism Of Action

ketoprofen – Drug Profile

Product Description

Mechanism Of Action

KU-32 – Drug Profile

Product Description

Mechanism Of Action

History of Events

MDR-16523 – Drug Profile

Product Description

Mechanism Of Action

MDR-652 – Drug Profile

Product Description

Mechanism Of Action

NSI-189 – Drug Profile

Product Description

Mechanism Of Action

History of Events

PDA-002 – Drug Profile

Product Description

Mechanism Of Action

History of Events

PGDN-20WS – Drug Profile

Product Description

Mechanism Of Action

History of Events

pirenzepine – Drug Profile

Product Description

Mechanism Of Action

History of Events

PTG-6 – Drug Profile

Product Description

Mechanism Of Action

History of Events

PTG-640 – Drug Profile

Product Description

Mechanism Of Action

PTG-641 – Drug Profile

Product Description

Mechanism Of Action

History of Events

resiniferatoxin – Drug Profile

Product Description

Mechanism Of Action

History of Events

RTA-901 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule for Algodystrophy, Chemotherapy Induced Peripheral Neuropathy, Diabetic Peripheral Neuropathy and Pain – Drug Profile

Product Description

Mechanism Of Action

Small Molecule for Diabetic Peripheral Neuropathy – Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Agonize MOR1 for Chemotherapy Induced Peripheral Neuropathy, Diabetic Peripheral Neuropathy and Postherpetic Neuralgia – Drug Profile

Product Description

Mechanism Of Action

SON-081 – Drug Profile

Product Description

Mechanism Of Action

History of Events

SYHA-1402 – Drug Profile

Product Description

Mechanism Of Action

History of Events

UI-048 – Drug Profile

Product Description

Mechanism Of Action

YJ-001 – Drug Profile

Product Description

Mechanism Of Action

Diabetic Peripheral Neuropathy – Dormant Projects

Diabetic Peripheral Neuropathy – Discontinued Products

Diabetic Peripheral Neuropathy – Product Development Milestones

Featured News & Press Releases

May 13, 2021: Pure Green Pharmaceuticals reports unexpected results of a randomized, placebo controlled clinical trial with sublingual CBD in patients with painful diabetic peripheral neuropathy

Sep 30, 2020: Praetego receives NIH phase 2 STTR funding to advance novel amadorin drug candidates for diabetic peripheral neuropathy

Sep 04, 2016: Salvianolic acid A tablets developed by the National Drug Screening Center received clinical approval

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Diabetic Peripheral Neuropathy, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Diabetic Peripheral Neuropathy – Pipeline by Achelios Therapeutics Inc, 2022

Diabetic Peripheral Neuropathy – Pipeline by Annji Pharmaceutical Co Ltd, 2022

Diabetic Peripheral Neuropathy – Pipeline by Applied Therapeutics Inc, 2022

Diabetic Peripheral Neuropathy – Pipeline by Celularity Inc, 2022

Diabetic Peripheral Neuropathy – Pipeline by CSPC Pharmaceutical Group Ltd, 2022

Diabetic Peripheral Neuropathy – Pipeline by Exodos Life Sciences Limited Partnership, 2022

Diabetic Peripheral Neuropathy – Pipeline by G&P Bioscience Co Ltd, 2022

Diabetic Peripheral Neuropathy – Pipeline by GNT Pharma Co Ltd, 2022

Diabetic Peripheral Neuropathy – Pipeline by Grunenthal GmbH, 2022

Diabetic Peripheral Neuropathy – Pipeline by Immune Pharmaceuticals Inc, 2022

Diabetic Peripheral Neuropathy – Pipeline by Ion Channel Pharmacology LLC, 2022

Diabetic Peripheral Neuropathy – Pipeline by Jiangsu Aosaikang Pharmaceutical Co Ltd, 2022

Diabetic Peripheral Neuropathy – Pipeline by Korea United Pharm Inc, 2022

Diabetic Peripheral Neuropathy – Pipeline by Medifron DBT Co Ltd, 2022

Diabetic Peripheral Neuropathy – Pipeline by Mitsubishi Tanabe Pharma Corp, 2022

Diabetic Peripheral Neuropathy – Pipeline by Palisade Bio, Inc, 2022

Diabetic Peripheral Neuropathy – Pipeline by Praetego Inc, 2022

Diabetic Peripheral Neuropathy – Pipeline by Pure Green Pharmaceuticals Inc, 2022

Diabetic Peripheral Neuropathy – Pipeline by Reata Pharmaceuticals Inc, 2022

Diabetic Peripheral Neuropathy – Pipeline by Shandong Huizhi Pharmaceutical Technology Co Ltd, 2022

Diabetic Peripheral Neuropathy – Pipeline by Sonnet BioTherapeutics Holdings Inc, 2022

Diabetic Peripheral Neuropathy – Pipeline by Sphaera Pharma Pte Ltd, 2022

Diabetic Peripheral Neuropathy – Pipeline by Winsantor Inc, 2022

Diabetic Peripheral Neuropathy – Pipeline by Zhejiang Pharmaceutical Co Ltd, 2022

Diabetic Peripheral Neuropathy – Dormant Projects, 2022

Diabetic Peripheral Neuropathy – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Diabetic Peripheral Neuropathy, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Diabetic Peripheral Neuropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Diabetic Peripheral Neuropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Diabetic Peripheral Neuropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.